Analysts forecast that Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Rating) will announce earnings per share of ($0.43) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Indaptus Therapeutics’ earnings. Indaptus Therapeutics posted earnings of ($5.53) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 92.2%. The firm is expected to report its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that Indaptus Therapeutics will report full year earnings of ($2.15) per share for the current fiscal year, with EPS estimates ranging from ($2.45) to ($1.85). For the next fiscal year, analysts anticipate that the company will post earnings of ($2.74) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Indaptus Therapeutics.
A number of research analysts have issued reports on INDP shares. Zacks Investment Research raised shares of Indaptus Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a report on Tuesday, April 5th. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Indaptus Therapeutics in a report on Monday, January 31st.
NASDAQ INDP opened at $2.47 on Friday. The company has a fifty day simple moving average of $3.43 and a two-hundred day simple moving average of $4.79. Indaptus Therapeutics has a 12-month low of $2.13 and a 12-month high of $28.83.
Indaptus Therapeutics Company Profile (Get Rating)
Indaptus Therapeutics, Inc, a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial.
- Get a free copy of the StockNews.com research report on Indaptus Therapeutics (INDP)
- VMWare Inc: Strong Revenues and Excellent Potential
- Etsy Buy!: Why Etsy Stock is Making a Crafty Comeback
- FIGS, Inc Moves Lower On Analysts’ Downgrades
- Option Care Health Stock is Making a Healthy Pullback
- MarketBeat Podcast: Trading Volatile Markets While Preserving Capital
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.